BRAIN Biotech AG (LTS:0RFI) PB Ratio: (As of Jul. 16, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0RFI BRAIN Biotech AG LTS:0RFI
60 GF Score
Price €2.91
GF Value €2.70
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is BRAIN Biotech AG PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-16), BRAIN Biotech AG's share price is €2.91. BRAIN Biotech AG's Book Value per Share for the quarter that ended in Mar. 2026 was €-0.18. Hence, BRAIN Biotech AG's PB Ratio of today is .

The historical rank and industry rank for BRAIN Biotech AG's PB Ratio or its related term are showing as below:

During the past 11 years, BRAIN Biotech AG's highest PB Ratio was 43.57. The lowest was 1.96. And the median was 8.07.

LTS:0RFI's PB Ratio is not ranked *
in the Chemicals industry.
Industry Median: 1.7
* Ranked among companies with meaningful PB Ratio only.

During the past 12 months, BRAIN Biotech AG's average Book Value Per Share Growth Rate was -164.40% per year. During the past 3 years, the average Book Value Per Share Growth Rate was -60.40% per year. During the past 5 years, the average Book Value Per Share Growth Rate was -37.20% per year. During the past 10 years, the average Book Value Per Share Growth Rate was -12.20% per year.

During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of BRAIN Biotech AG was 45.40% per year. The lowest was -60.40% per year. And the median was -10.55% per year.

Back to Basics: PB Ratio


BRAIN Biotech AG  (LTS:0RFI) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


BRAIN Biotech AG PB Ratio Related Terms


BRAIN Biotech AG PB Ratio Historical Data

* Premium members only.

The historical data trend for BRAIN Biotech AG's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BRAIN Biotech AG PB Ratio Chart

BRAIN Biotech AG Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.54 3.25 4.51 3.39 26.79

BRAIN Biotech AG Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.47 7.90 26.79 0.00 0.00

LTS:0RFI vs LIN, SHW, ECL: PB Ratio Comparison

For the Specialty Chemicals subindustry, BRAIN Biotech AG's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BRAIN Biotech AG PB Ratio vs Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's PB Ratio distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's PB Ratio falls into.


LTS:0RFI
60GF Score
BRAIN Biotech AG LTS:0RFI
PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BRAIN Biotech AG PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

BRAIN Biotech AG's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Mar. 2026)
=2.91/-0.177
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.

Is BRAIN Biotech AG (LTS:0RFI) Overvalued in 2026?

Based on GuruFocus' analysis, BRAIN Biotech AG stock appears to be overvalued. The current stock price of €2.91 is trading 7.8% above its estimated GF Value™ of €2.70. GuruFocus considers BRAIN Biotech AG to be Fairly Valued.

Key valuation signals for LTS:0RFI:

  • PB Ratio:
  • GF Value™: €2.70 vs. price of €2.91 (7.8% above fair value)
  • GF Score™: 60/100 with 2 warning signs

No single metric tells the full story. See the LTS:0RFI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


BRAIN Biotech AG Business Description

Other Exchanges BNN:Germany
Address Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673
BRAIN Biotech AG is an industrial biotechnology specialist focused on enzyme technology, microbial production strains, and bioprocess design to enable bio-based innovations. The Group conducts research, development, and production for client specifications and its own product portfolio, supporting customers in the food and beverage, chemical, and life sciences industries with solutions that enhance productivity, efficiency, and sustainability. Its operations are organized into two segments: BRAIN Biocatalysts, which develops, produces, and distributes specialty enzymes, microorganisms, and ingredients and generates the majority of revenue, and BRAIN BioIncubator, which focuses on development projects. The company operates in Germany and other countries.
60GF Score

Get the complete analysis for LTS:0RFI

PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.91
Price
€2.70
GF Value